<DOC>
	<DOC>NCT01516567</DOC>
	<brief_summary>Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.</brief_summary>
	<brief_title>Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically proven Primary Mediastinal Large BCell Lymphoma (PMLBL). PMLBL without central nervous system (CNS) involvement. 6 months to less than 18 years of age at the time of consent. Males and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab Complete initial workup within 8 days prior to treatment that allows definite staging. Able to comply with scheduled followup and with management of toxicity. Signed informed consent from patients and/or their parents or legal guardians Follicular lymphoma, mucosaassociated lymphoid tissue (MALT) and nodular marginal zone PMLBL patients with CNS involvement Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology. Evidence of pregnancy or lactation period. There will be no exclusion criteria based on organ function. Past or current anticancer treatment except corticosteroids during less than one week. Tumor cell negative for CD20 Prior exposure to rituximab. Severe active viral infection, especially hepatitis B. Hepatitis B carrier status history of hepatitis B virus (HBV) or positive serology. Participation in another investigational drug clinical trial. Patients who, for any reason, are not able to comply with the national legislation.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>